{
  "id": "602828b11cb411341a0000fc",
  "type": "factoid",
  "question": "Which molecule is targeted by Camrelizumab?",
  "ideal_answer": "Camrelizumab is a humanised antibody that targets programmed death-1 (PD-1) ligand.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31939447",
    "http://www.ncbi.nlm.nih.gov/pubmed/31939448",
    "http://www.ncbi.nlm.nih.gov/pubmed/30213452",
    "http://www.ncbi.nlm.nih.gov/pubmed/32112738",
    "http://www.ncbi.nlm.nih.gov/pubmed/32376724",
    "http://www.ncbi.nlm.nih.gov/pubmed/32499235",
    "http://www.ncbi.nlm.nih.gov/pubmed/31017739",
    "http://www.ncbi.nlm.nih.gov/pubmed/32416073",
    "http://www.ncbi.nlm.nih.gov/pubmed/33004770",
    "http://www.ncbi.nlm.nih.gov/pubmed/32256049",
    "http://www.ncbi.nlm.nih.gov/pubmed/32623573",
    "http://www.ncbi.nlm.nih.gov/pubmed/32602470",
    "http://www.ncbi.nlm.nih.gov/pubmed/32411597",
    "http://www.ncbi.nlm.nih.gov/pubmed/33087333",
    "http://www.ncbi.nlm.nih.gov/pubmed/32762583",
    "http://www.ncbi.nlm.nih.gov/pubmed/31420358",
    "http://www.ncbi.nlm.nih.gov/pubmed/33154554",
    "http://www.ncbi.nlm.nih.gov/pubmed/31238988",
    "http://www.ncbi.nlm.nih.gov/pubmed/33299330",
    "http://www.ncbi.nlm.nih.gov/pubmed/30242068",
    "http://www.ncbi.nlm.nih.gov/pubmed/31313098",
    "http://www.ncbi.nlm.nih.gov/pubmed/31039052",
    "http://www.ncbi.nlm.nih.gov/pubmed/32776600",
    "http://www.ncbi.nlm.nih.gov/pubmed/33092443",
    "http://www.ncbi.nlm.nih.gov/pubmed/33097476",
    "http://www.ncbi.nlm.nih.gov/pubmed/33241036",
    "http://www.ncbi.nlm.nih.gov/pubmed/32064977",
    "http://www.ncbi.nlm.nih.gov/pubmed/32530632",
    "http://www.ncbi.nlm.nih.gov/pubmed/33063473",
    "http://www.ncbi.nlm.nih.gov/pubmed/33194624",
    "http://www.ncbi.nlm.nih.gov/pubmed/33052760"
  ],
  "snippets": [
    {
      "text": "Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The PD-1 antibody camrelizumab was well tolerated in patients with nasopharyngeal carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30242068",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As decitabine is known to boost T-cell function, we assessed the safety and efficacy of anti-PD-1 camrelizumab alone versus decitabine-primed camrelizumab in patients with relapsed/refractory cHL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Decitabine plus camrelizumab may reverse resistance to PD-1 inhibitors in patients with relapsed/refractory cHL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039052",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION CR rate in patients with relapsed/refractory cHL who were clinically na\u00efve to PD-1 blockade was significantly higher with decitabine plus camrelizumab than with camrelizumab alone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As decitabine is known to boost T-cell function, we assessed the safety and efficacy of anti-PD-1 camrelizumab alone versus decitabine-primed camrelizumab in patients with relapsed/refractory cHL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent phase 1-2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regimens is lacking.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31238988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As decitabine is known to boost T-cell function, we assessed the safety and efficacy of anti-PD-1 camrelizumab alone versus decitabine-primed camrelizumab in patients with relapsed/refractory cHL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent phase 1-2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regimens is lacking.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31238988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we represent preliminary evidence for the comparative safety and efficacy of existing anti-PD-1 agents with/without chemotherapy in RM-NPC, which indicated that camrelizumab has the least toxicity profile and merits future investigation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31238988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Camrelizumab (AiRuiKa\u2122), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31313098",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31017739",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "All patients were administered intravenous camrelizumab (SHR-1210), a novel anti-PD-1 antibody, at doses of 60 mg, 200 mg, or 400 mg (4-week interval after first dose followed by a 2-week schedule) until disease progression or intolerable toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31017739",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we describe a case of a novel pattern of RRP induced by anti-PD-1 blockade Camrelizumab 2 years after radiotherapy, with some focus on further understanding of this phenomenon. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After 15 months, due to tumor progression and brain metastasis, he started with administration of anti-PD-1 blockade Camrelizumab (200 mg q2w) and stereotactic radiosurgery (SRS). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed to assess efficacy and safety of the anti-PD-1 antibody camrelizumab versus investigator's choice of chemotherapy in previously treated patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32416073",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study aimed to assess the antitumour activity and safety of the anti-PD-1 inhibitor camrelizumab in pretreated patients with advanced hepatocellular carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32112738",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In our present report, we described a newly diagnosed non-small-cell lung cancer\u00a0patient who suffered from focal vitiligo for approximately ten\u00a0years and was treated with the anti-programmed cell death-1 receptor\u00a0antibody camrelizumab (SHR-1210), which accelerated the aggravation of depigmentation of the skin over the whole body in just half a year.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32064977",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PATIENTS AND METHODS: In this open-label, single-arm, phase II study, the safety and efficacy of combined regimen of chemotherapy consisting of gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) plus anti-PD-1 antibody camrelizumab was assessed in rrPMBCL. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32499235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32376724",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We further benchmarked the dissociation kinetics for three clinically approved PD-1 blockade mAbs (Nivolumab, Pembrolizumab, and Camrelizumab), intriguingly correlating well with the objective response rates in the hepatocellular carcinoma second-line treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32530632",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Purpose: Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32256049",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Camrelizumab is a programmed cell death protein 1 inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33092443",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "sions: Our findings suggest that (I) PD-1 targeted immunotherapy with toripalimab, camrelizumab, or sintilimab yielded a promising outcome in Chinese HBV patients with HCC and that (II) immunotherapy was well tolerated generally and had manageable side effects. This ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33241036",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ately, the tumors dramatically shrank after one cycle of camrelizumab, an anti-programmed cell death-1 (PD-1) antibody developed by Chinese Hengrui Medicine. In concl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33299330",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33299330",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "JECTIVE: To evaluate the immune-related adverse events (irAEs) induced by Camrelizumab, an anti-PD-1 antibody in a patient with gastric cancer.C",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32602470",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RT OPINION: Camrelizumab is a selective, humanized, high-affinity IgG4 kappa mAb against PD-1. Ca",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32762583",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Camrelizumab (also known as SHR-1210), a humanized monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape of tumor cells",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32762583",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The structure of the camrelizumab/PD-1 complex reveals that camrelizumab mainly utilizes its heavy chain to bind to PD-1, while the light chain sterically inhibits the binding of PD-L1 to PD-1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33063473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we demonstrate varied N-glycan composition in PD-1, and show that the binding affinity of camrelizumab, a recently approved PD-1-specific MAb, to non-glycosylated PD-1 proteins from E.\u00a0coli is substantially decreased compared with glycosylated PD-1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33063473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study aimed to assess the antitumour activity and safety of the anti-PD-1 inhibitor camrelizumab in pretreated patients with advanced hepatocellular carcinoma.M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32112738",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Camrelizumab (also known as SHR-1210), a humanized monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape o",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32762583",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Purpose: Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32256049",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Camrelizumab (AiRuiKa\u2122), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31313098",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The PD-1 antibody camrelizumab plus the VEGFR2 inhibitor apatinib had efficacy in a phase II trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33097476",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: We assessed the efficacy and safety of camrelizumab (an anti-PD-1 monoclonal antibody) plus apatinib (a vascular endothelial growth factor [VEGFR]-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33087333",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, all three patients responded to low-dose decitabine, an epigenetic drug, in combination with camrelizumab (anti-PD-1 antibody), with only controllable adverse events, indicating that low-dose decitabine can sensitize PD-1/PD-L1 inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33194624",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: Camrelizumab is a promising anti-programmed cell death-1 agent for non-small cell lung cancer (NSCLC) and induces reactive capillary hemangiomas (RCHs). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31939447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Camrelizumab is a programmed cell death protein 1 inhibitor; however, current evidence of its efficacy in PSC is lacking.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32776600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Camrelizumab is a programmed death receptor-1 inhibitor originally developed in China for the treatment of refractory lymphoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33004770",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent phase 1-2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regimens is lacking. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31238988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Camrelizumab, a programmed cell death 1 (PD-1) inhibitor, has been approved for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma, nasopharyngeal cancer and non-small cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33154554",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Camrelizumab is an antibody against programmed death protein 1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33052760",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All patients were administered intravenous camrelizumab (SHR-1210), a novel anti-PD-1 antibody, at doses of 60 mg, 200 mg, or 400 mg (4-week interval after first dose followed by a 2-week schedule) until disease progression or intolerable toxicity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31017739",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, we explored the efficacy and safety of a PD-1 checkpoint inhibitor camrelizumab in advanced or metastatic solid tumour with dMMR/MSI-H.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32623573",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aim: The present study evaluated the safety and efficacy of camrelizumab (a programmed death-1 antibody) in combination with microwave ablation (MWA) in advanced non-small cell lung cancer (NSCLC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31939448",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "PD-1, programmed death-1"
}